VNRX
VolitionRx Limited
NYSE AmericanUSDEQUITY
Healthcare
DELAYED
Sell
-39/100
Last price
0.24
▲ 0.01 (4.70%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
0.24
Prev close
0.23
Day high
0.25
Day low
0.23
Volume
643.67K
Market cap
$7.30M
P/E (TTM)
—
52W range
0.23 – 13.40
Day trading desk
Gap from prior close
+5.61%
Prior close 0.23
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
1.21%
0.24 – 0.24
Position in range
100%
Near session high
ATR (14D)
0.02
7.35% of price
Prior day high
0.24
PDH
Prior day low
0.23
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 8.44M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-7.69%
-9.6%
1M
-31.43%
-32.6%
3M
-82.22%
-86.7%
6M
-92.94%
-111.1%
YTD
-95.38%
-109.6%
1Y
-98.15%
-114.6%
3Y
-98.26%
-180.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on VNRX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+13.17M
Net buying
Buy transactions
312
13.40M shares
Sell transactions
11
230.69K shares
Net transactions
+323
Buys less sells
Sell : buy shares
0.0 : 1
Mixed
Insider-held shares
453.43K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Feb 26, 26 | REYNOLDS CAMERON JOHN Chief Executive Officer |
— | 486.00K | — | Direct |
| Feb 26, 26 | INNES GUY ARCHIBALD Director |
— | 178.00K | — | Direct |
| Feb 26, 26 | ROOTSAERT RODNEY GERARD Officer |
— | 119.00K | — | Direct |
| Feb 26, 26 | MICALLEF JACOB VINCENT Officer |
— | 149.00K | — | Direct |
| Feb 26, 26 | KWAY JASMINE Officer |
— | 173.00K | — | Direct |
| Feb 26, 26 | HUGHES TERIG Chief Financial Officer |
— | 202.00K | — | Direct |
| Feb 26, 26 | FORTERRE GAEL Officer |
— | 149.00K | — | Direct |
| Feb 26, 26 | NGUYEN KIM Director |
— | 178.00K | — | Direct |
| Feb 26, 26 | PLUMMER NICHOLAS Officer |
— | 187.00K | — | Direct |
| Feb 26, 26 | BATCHELOR ANN-LOUISE Officer |
— | 142.00K | — | Direct |
| Feb 26, 26 | RUBIN ETHEL Director |
— | 178.00K | — | Direct |
| Jan 22, 26 | REYNOLDS CAMERON JOHN Chief Executive Officer |
— | 74.70K | — | Direct |
| Jan 22, 26 | STILL TIMOTHY I Director |
— | 90.00K | — | Direct |
| Jan 22, 26 | INNES GUY ARCHIBALD Director |
— | 12.00K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BUTERA SALVATORE THOMAS |
Officer | 474.55K | Stock Award(Grant) |
FORTERRE GAEL |
Officer | 376.37K | Stock Award(Grant) |
HUGHES TERIG |
Chief Financial Officer | 684.97K | Stock Award(Grant) |
INNES GUY ARCHIBALD |
Director | 3.63M | Stock Award(Grant) |
KWAY JASMINE |
Officer | 429.01K | Stock Award(Grant) |
MICALLEF JACOB VINCENT |
Officer | 670.60K | Stock Award(Grant) |
PLUMMER NICHOLAS |
Officer | 420.14K | Stock Award(Grant) |
REYNOLDS CAMERON JOHN |
Chief Executive Officer | 4.16M | Stock Award(Grant) |
ROOTSAERT RODNEY GERARD |
Officer | 1.29M | Stock Award(Grant) |
STILL TIMOTHY I |
Director | 1.63M | Stock Award(Grant) |
Fundamentals
Market cap$7.30M
Enterprise value$10.56M
Revenue (TTM)$2.46M
Gross profit$2.46M
EBITDA$-18.57M
Net income$-26.10M
EPS (TTM)$-3.80
Free cash flow$-9.21M
Total cash$2.79M
Total debt$11.41M
Book value / share$-2.67
Shares outstanding30.06M
Float12.06M
Short % of float3.66%
Dividend yield0.00%
Beta (5Y)1.17
Valuation & profitability ratios
Trailing P/E—
Forward P/E-0.29
PEG ratio—
Price / sales—
Price / book—
EV / revenue4.30
EV / EBITDA-0.57
Gross margin100.00%
Operating margin-1042.50%
Profit margin0.00%
Return on equity—
Return on assets-142.94%
Debt / equity—
Current ratio0.30
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $1.73M | $1.23M | $775.30K | $306.39K | +40.0% |
| Operating revenue | $1.73M | $1.23M | $775.30K | $306.39K | +40.0% |
| Research & development | $10.08M | $14.41M | $19.55M | $15.33M | -30.0% |
| Selling, general & admin | $13.20M | $13.64M | $16.92M | $16.40M | -3.2% |
| Total operating expense | $22.95M | $28.16M | $36.55M | $30.86M | -18.5% |
| Operating income | -$21.22M | -$26.92M | -$35.77M | -$30.55M | +21.2% |
| Net interest income | -$2.49M | -$330.42K | -$128.30K | -$47.82K | -653.2% |
| Pre-tax income | -$23.50M | -$27.26M | -$35.68M | -$30.60M | +13.8% |
| Net income | -$23.36M | -$26.97M | -$35.32M | -$30.27M | +13.4% |
| Net income to common | -$23.36M | -$26.97M | -$35.32M | -$30.27M | +13.4% |
| Basic EPS | -4.40 | -6.20 | -10.00 | -11.00 | +29.0% |
| Diluted EPS | -4.40 | -6.20 | -10.00 | -11.00 | +29.0% |
| EBIT | -$21.01M | -$26.92M | -$35.46M | -$30.43M | +21.9% |
| EBITDA | -$19.80M | -$25.58M | -$34.04M | -$29.24M | +22.6% |
| Basic shares | 5.34M | 4.33M | 3.56M | 2.77M | +23.5% |
| Diluted shares | 5.34M | 4.33M | 3.56M | 2.77M | +23.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $1.12M | $3.26M | $20.73M | $10.87M | -65.8% |
| Cash & short-term investments | $1.12M | $3.26M | $20.73M | $10.87M | -65.8% |
| Accounts receivable | $317.81K | $110.57K | $242.62K | $72.61K | +187.4% |
| Total current assets | $2.06M | $4.06M | $21.85M | $12.17M | -49.2% |
| Property, plant & equipment | $4.52M | $5.03M | $6.07M | $6.01M | -10.0% |
| Goodwill & intangibles | $316.70K | $313.75K | $23.89K | $110.50K | +0.9% |
| Total assets | $6.90M | $9.40M | $27.95M | $18.30M | -26.6% |
| Total current liabilities | $12.23M | $7.79M | $8.94M | $17.39M | +57.0% |
| Current debt | $3.31M | $860.22K | $1.21M | $1.07M | +284.6% |
| Long-term debt | $7.26M | $3.95M | $3.62M | $2.78M | +83.6% |
| Total debt | $11.46M | $5.82M | $5.86M | $4.97M | +97.0% |
| Total liabilities | $42.49M | $35.51M | $36.66M | $21.42M | +19.7% |
| Retained earnings | -$252.90M | -$229.54M | -$202.58M | -$167.26M | -10.2% |
| Shareholder equity | -$34.25M | -$24.91M | -$7.80M | -$2.57M | -37.5% |
| Working capital | -$10.17M | -$3.73M | $12.91M | -$5.21M | -172.4% |
| Net tangible assets | -$34.56M | -$25.22M | -$7.83M | -$2.69M | -37.0% |
| Shares issued | 6.29M | 4.80M | 4.09M | 2.89M | +30.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$23.50M | -$27.26M | -$35.68M | -$30.60M | — | +13.8% |
| Depreciation & amortisation | $1.22M | $1.34M | $1.41M | $1.19M | — | -9.2% |
| Stock-based compensation | $1.74M | $1.27M | $2.29M | $3.11M | — | +37.1% |
| Change in working capital | -$885.80K | -$1.25M | $14.14M | $11.02M | — | +29.1% |
| Operating cash flow | -$19.68M | -$25.89M | -$18.06M | -$15.28M | — | +24.0% |
| Capital expenditure | -$89.56K | -$573.85K | -$1.08M | -$1.57M | — | +84.4% |
| Investing cash flow | -$89.56K | -$573.85K | -$1.08M | -$1.57M | — | +84.4% |
| Share buybacks | — | $0 | -$31.77K | $0 | $0 | — |
| Financing cash flow | $17.09M | $8.66M | $28.98M | $6.94M | — | +97.4% |
| Free cash flow | -$19.77M | -$26.47M | -$19.15M | -$16.85M | — | +25.3% |
| End cash position | $1.12M | $3.26M | $20.73M | $10.87M | — | -65.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $398.66K | $985.08K | $447.03K | $627.28K | $406.69K | — | -59.5% |
| Operating revenue | $398.66K | $985.08K | $447.03K | $627.28K | $406.69K | — | -59.5% |
| Research & development | $1.80M | $2.85M | $2.47M | $2.29M | $2.72M | — | -36.9% |
| Selling, general & admin | $2.72M | $3.44M | $2.76M | $3.40M | $3.94M | — | -21.0% |
| Total operating expense | $4.60M | $6.21M | $5.18M | $5.50M | $6.63M | — | -26.0% |
| Operating income | -$4.20M | -$5.23M | -$4.73M | -$4.87M | -$6.22M | — | +19.6% |
| Net interest income | -$1.15M | -$575.96K | -$1.07M | -$873.27K | -$448.50K | — | -98.8% |
| Pre-tax income | -$7.32M | -$6.70M | -$6.30M | -$5.41M | -$6.31M | — | -9.1% |
| Net income | -$7.33M | -$6.66M | -$6.27M | -$5.38M | -$6.28M | — | -9.9% |
| Net income to common | -$7.79M | -$6.66M | -$6.27M | -$5.38M | -$6.28M | — | -16.8% |
| Basic EPS | -0.85 | -0.97 | — | -1.00 | -1.22 | -1.12 | +12.4% |
| Diluted EPS | -0.85 | -0.97 | — | -1.00 | -1.22 | -1.12 | +12.4% |
| EBIT | -$6.17M | -$6.13M | -$5.23M | -$4.54M | -$5.87M | — | -0.7% |
| EBITDA | -$5.88M | -$5.87M | -$4.95M | -$4.23M | -$5.55M | — | -0.2% |
| Basic shares | 9.15M | 6.88M | — | 5.41M | 5.13M | 4.83M | +33.0% |
| Diluted shares | 9.15M | 6.88M | — | 5.41M | 5.13M | 4.83M | +33.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $2.79M | $3.10M | $1.12M | $199.41K | $2.26M | -10.0% |
| Cash & short-term investments | $2.79M | $3.10M | $1.12M | $199.41K | $2.26M | -10.0% |
| Accounts receivable | $277.36K | $252.24K | $317.81K | $309.08K | $189.60K | +10.0% |
| Total current assets | $4.09M | $4.52M | $2.06M | $1.33M | $3.26M | -9.4% |
| Property, plant & equipment | $3.90M | $4.20M | $4.52M | $4.82M | $5.14M | -7.1% |
| Goodwill & intangibles | $305.13K | $318.90K | $316.70K | $301.03K | $306.38K | -4.3% |
| Total assets | $8.30M | $9.04M | $6.90M | $6.45M | $8.70M | -8.1% |
| Total current liabilities | $13.49M | $13.57M | $12.23M | $11.42M | $9.24M | -0.6% |
| Current debt | $4.49M | $4.26M | $3.31M | $2.44M | $1.18M | +5.4% |
| Long-term debt | $6.22M | $6.63M | $7.26M | $7.82M | $8.69M | -6.2% |
| Total debt | $11.41M | $11.70M | $11.46M | $11.26M | $10.94M | -2.5% |
| Total liabilities | $41.84M | $42.40M | $42.49M | $42.40M | $41.80M | -1.3% |
| Retained earnings | -$267.35M | -$259.57M | -$252.90M | -$246.63M | -$241.25M | -3.0% |
| Shareholder equity | -$32.16M | -$31.97M | -$34.25M | -$34.64M | -$31.82M | -0.6% |
| Working capital | -$9.40M | -$9.05M | -$10.17M | -$10.09M | -$5.98M | -3.9% |
| Net tangible assets | -$32.47M | -$32.29M | -$34.56M | -$34.94M | -$32.12M | -0.5% |
| Shares issued | 12.04M | 7.93M | 6.29M | 5.48M | 5.20M | +51.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$7.32M | -$6.70M | -$6.30M | -$5.41M | -$6.31M | — | -9.1% |
| Depreciation & amortisation | $285.54K | $254.41K | $280.56K | $309.03K | $318.54K | — | +12.2% |
| Stock-based compensation | $238.00K | $224.98K | -$132.88K | $609.17K | $812.04K | — | +5.8% |
| Change in working capital | -$1.34M | -$405.38K | -$739.37K | $462.83K | -$1.05M | — | -230.9% |
| Operating cash flow | -$5.16M | -$5.28M | -$5.49M | -$3.63M | -$6.26M | — | +2.3% |
| Capital expenditure | -$1.79K | -$9.21K | -$10.97K | — | -$76.78K | -$1.81K | +80.6% |
| Investing cash flow | -$1.79K | -$9.21K | -$10.97K | $0 | -$76.78K | — | +80.6% |
| Financing cash flow | $4.98M | $7.62M | $6.16M | $1.60M | $5.67M | — | -34.6% |
| Free cash flow | -$5.16M | -$5.29M | -$5.50M | -$3.63M | -$6.34M | — | +2.4% |
| End cash position | $2.79M | $3.10M | $1.12M | $199.41K | $2.26M | — | -10.0% |
Options analytics
Put / call volume
1.50
Put-heavy session
Put / call open interest
0.23
Positioning, not flow
Max pain
2.50
+929.2% from spot
ATM implied vol
50.0%
Nearest strike to spot
Skew (10% OTM)
-50.0%
Calls bid over puts
Call volume
4
Contracts, this expiry
Put volume
6
Contracts, this expiry
Heaviest call OI
2.50
405 contracts
Heaviest put OI
5.00
115 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.67 | -0.59 | +12.7% |
| Mar 2026 | -0.73 | -0.84 | -14.2% |
| Dec 2025 | -0.80 | -0.91 | -13.5% |
| Sep 2025 | -1.04 | -1.06 | -1.6% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.31 | 1 | $696.15K | +11.0% |
| Next quarter | -0.29 | 1 | $709.95K | +58.8% |
| Current year | -2.00 | 1 | $2.72M | +57.7% |
| Next year | -0.85 | 1 | $9.27M | +240.5% |
Analyst targets & ownership
Mean target$13.62
High target$24.00
Low target$2.00
Implied upside5508.07%
Analyst count5
ConsensusNONE
Strong buy / Buy1 / 3
Hold1
Sell / Strong sell0 / 0
Held by insiders3.32%
Held by institutions10.80%
Institutions holding30
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
0.25
-1.66% from price
SMA 20
0.27
-10.95% from price
SMA 50
0.45
-46.45% from price
SMA 100
1.05
-76.95% from price
SMA 200
2.66
-90.97% from price
EMA 12
0.25
-4.73% from price
EMA 26
0.32
-24.30% from price
EMA 50
0.53
-54.22% from price
RSI (14)
30.1
Neutral
MACD (12,26,9)
-0.07
Hist 0.01
ATR (14)
0.02
7.44% of price
Realised vol 30D
142.0%
Annualised
Bollinger upper
0.33
20, 2σ
Bollinger lower
0.21
20, 2σ
50 / 200 cross
Death
0.45 vs 2.66
Trend bias
Below 200
-90.97%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.37
More volatile than market
Correlation to SPY
0.16
Largely independent
Realised vol 30D
142.0%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-98.2%
Peak to trough
Max drawdown 5Y
-99.7%
Peak to trough
ATR 14
0.02
7.44% of price
Beta (reported)
1.17
5Y monthly, from filing
Short interest
Shares short
1.00M
Prior 683.89K
Change vs prior
+46.9%
Shorts adding
% of float
3.66%
Normal
% of shares out
3.60%
Against total outstanding
Days to cover
0.1
Liquid
Float
12.06M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 20, 26 | D. Boral Capital | DOWNGRADE | Buy | Hold |
| Apr 2, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 31, 26 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Mar 26, 26 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Mar 18, 26 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Jan 21, 26 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Jan 9, 26 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Dec 18, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Dec 4, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Dec 3, 25 | Maxim Group | DOWNGRADE | Buy | Hold |
| Nov 26, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Nov 21, 25 | Freedom Broker | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split1:20
Split dateApr 28, 2026
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-25
Corporate Changes & Voting Matters
8-K · 2026-09-15
Corporate Changes & Voting Matters
8-K · 2026-09-14
Offering Registrations
S-3/A · 2026-09-09
Offering Registrations
S-3/A · 2026-09-08
Corporate Changes & Voting Matters
8-K · 2026-09-02
Offering Registrations
S-3 · 2026-08-28
Corporate Changes & Voting Matters
8-K · 2026-08-24
Headlines
VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France
PR Newswire · 20d ago
VolitionRx Participates in Launch of DETECSEPS Program in France
PR Newswire · 20d ago
VNRX: VolitionRx Prepays Outstanding Balance on the $7,500,000 Lind Senior Secured Convertible Promissory Note Dated May 20, 2025. Review of Papers, Posters, and Videos Released in Mid-2026. Sysmex Collaboration is the 3rd Recent Agreement in the Human Space.
Zacks Small Cap Research · 23d ago
VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027
PR Newswire · 23d ago
Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference
PR Newswire · 27d ago
Penny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations
Benzinga · 41d ago
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
PR Newswire · 42d ago
Volition Announces Landmark Clinical Validation of Nu.Q® NETs Biomarker in Sepsis
PR Newswire · 42d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.